Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 1602-1603, 2006; 10.1373/clinchem.2006.069369
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fokkema, M. R.
Right arrow Articles by Moecks, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fokkema, M. R.
Right arrow Articles by Moecks, J.
Related Collections
Right arrow Current Issues in Laboratory Medicine
Right arrow Informatics and Statistics
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2006;52:1602-1603.)
© 2006 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Reference Change Values for Brain Natriuretic Peptides Revisited

M. Rebecca Fokkema1,a, Zuzana Herrmann2, Frits A.J. Muskiet1 and Joachim Moecks2

1 Pathology and Laboratory Medicine, University Medical Hospital Groningen, Groningen, The Netherlands
2 Roche Diagnostics GmbH, Mannheim, Germany

aAddress correspondence to this author at: University Medical Hospital Groningen, Department of Pathology and Laboratory Medicine, CMC-V, Room Y1.165, PO Box 30.001, 9700 RB Groningen, The Netherlands. E-mail m.r.fokkema@lc.umcg.nl.

The first 20% of the full text of this article appears below.


To the Editor:

In 2004, Bruins et al. (1) published a report in which they used the approach of Harris and Yasaka (2) to determine the reference change values (RCVs) for B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP). Week-to-week RCVs were 113% and 98%, respectively, meaning that concentrations had to increase or decrease by these percentages to be assessed as different from the previous measurement, with a 5% error probability for falsely assessing a change as significant. The clinical relevance of these large RCVs led to a lively discussion (3)(4)(5)(6) regarding RCV methodology. In response, we have developed some ideas for improving RCV calculation by addressing the skewness of the distribution.

The previous study used for the new approach investigated 43 patients with stable chronic heart failure by within-day, day-to-day, and week-to-week measurements of BNP (Abbott Diagnostics) and NT-proBNP (Elecsys® proBNP, Roche Diagnostics GmbH). For details, see the original report (1).

Natriuretic peptides are . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 CirculationHome page
F. S. Apple, A. H.B. Wu, A. S. Jaffe, M. Panteghini, R. H. Christenson, NACB COMMITTEE MEMBERS, R. H. Christenson, F. S. Apple, C. P. Cannon, G. Francis, et al.
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure
Circulation, July 31, 2007; 116(5): e95 - e98.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.